2. Signaling Pathways
  3. PROTAC
  4. Ligands for E3 Ligase
  5. Ligands for E3 Ligase Ligand

Ligands for E3 Ligase Ligand

Ligands for E3 Ligase Isoform Comparison

Ligands for E3 Ligase Ligands (8):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-122542B
    PPACK TFA 157379-44-7 99.80%
    PPACK TFA is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK TFA binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (Treg) into effector-like T cells, enhances CD8+ T cell responses, and modulates the Teff:Treg balance. PPACK TFA also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of Treg. PPACK TFA can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1.
    PPACK TFA
  • HY-159647
    PLX-4545 2892065-45-9
    PLX-4545 is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PLX-4545 binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (Treg) into effector-like T cells, enhances CD8+ T cell responses, and modulates the Teff:Treg balance. PLX-4545 also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of Treg. PLX-4545 can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1.
    PLX-4545
  • HY-122542A
    PPACK dihydrochloride 82188-90-7 99.07%
    PPACK dihydrochloride is an orally active, selective molecular glue degrader targeting IKZF2. Through a molecular glue mechanism, PPACK dihydrochloride binds to CRBN, recruits IKZF2 to form a ternary complex, and promotes its ubiquitination and proteasomal degradation. This further converts inhibitory regulatory T cells (Treg) into effector-like T cells, enhances CD8+ T cell responses, and modulates the Teff:Treg balance. PPACK dihydrochloride also increases the production of the inflammatory cytokine IL-2 and reduces the suppressive activity of Treg. PPACK dihydrochloride can be used in cancer immunotherapy research, and exhibits a synergistic effect when combined with immune checkpoint inhibitors such as anti-PD1.
    PPACK dihydrochloride
  • HY-W245311
    E3 ligase Ligand 51 2703915-71-1 98.42%
    E3 ligase Ligand 51 is the ligand for E3 ligase CRBN that can be used for synthesis of PROTAC BTK Degrader-12 (HY-170413).
    E3 ligase Ligand 51
  • HY-182983
    DDB1 ligand-1
    DDB1 ligand-1 is a DNA damage-binding protein 1 (DDB1) ligand. DDB1 ligand-1 binds to a unique pocket on the β propeller C (BPC) domain of DDB1, induces conformational changes, and blocks the canonical DCAF/HBx peptide binding site of DDB1. DDB1 ligand-1 engages full-length DDB1 in cellular settings and supports PROTAC development research.
    DDB1 ligand-1
  • HY-170986
    E3 ligase Ligand 57
    E3 ligase Ligand 57 is an E3 ligase ligand of MC-25B (HY-170983) which is a specific FKBP12 PROTAC.
    E3 ligase Ligand 57
  • HY-179168
    Thalidomide-C4-N2-C2-N3 2825005-43-2
    Thalidomide-C4-N2-C2-N3 is an E3 ligase ligand. Thalidomide-C4-N2-C2-N3 can bind to a target protein ligand with a linker to form a PROTAC molecule, PROTAC sEH-degrader-4 (HY-179166).
    Thalidomide-C4-N2-C2-N3
  • HY-157559
    KDRLKZ-2
    KDRLKZ-2 is a selective E3 ligase. KDRLKZ-2 is a ligand for KLHDC2, with an IC50 value of 0.068 μM in the alphaLISA experiment.
    KDRLKZ-2